Pay in 4 interest-free payments of $5.44 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Author information Authors and Affiliations The CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China Honglei Ma, Xiaoxi Wang, Lihua Zhao, Yi Jiang & H
When I came home the first time, I literally could not lift my leg
Abdel-Khalek AE, El-Ratel IT, Wafa WM, El-Nagar HA, Younan GE, Fouda SF
Our licensed medical providers evaluate each patient individually to determine whether this medication may be an appropriate part of a comprehensive medical weight loss plan
Most common adverse events at all doses: Nausea (3355%, dose-related) Vomiting (1335%) Decreased appetite (1528%) Constipation or diarrhea (1020%) Injection-site reaction (510%) Dose-related dysesthesia signal: The TRIUMPH-4 trial identified a dose-related dysesthesia (nerve-tingling, paresthesia) signal: This is the most-flagged trial-level safety signal for retatrutide and the reason community doses cluster at 2-4 mg/week well below where the dysesthesia signal becomes prominent
